RxDoctor Payments Data

Gregory Sahagian, MD

Neurology · Carlsbad, CANPI 1831132109

Payments from drug & device makers

$981,454in general payments, 2019–2025

Across 1,308 payments — averaging $750.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$529K
  • Argenx US, Inc.$370K
  • UCB, Inc.$35K
  • AbbVie$23K
  • Alnylam Pharmaceuticals Inc.$8K
  • Biogen$5K
  • plus $11K from 54 others
$1,212in research payments, 2019–2025

Across 7 payments — averaging $173.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1K

What the payments were for

  • Consulting fees$44,23732%
  • Speaking & faculty fees$68,17050%
  • Travel & lodging$11,4098%
  • Food & beverage$13,79210%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron649$529,009
Argenx US, Inc.203$370,342
UCB, Inc.69$35,014
AbbVie(2 entities)104$22,554
Alnylam Pharmaceuticals Inc.4$8,221
Biogen24$5,388
AstraZeneca18$3,216
Amgen(2 entities)13$2,751
Sunovion Pharmaceuticals Inc.59$931
Novartis24$547
Lilly USA, LLC10$244
Inspire Medical Systems, Inc.1$229
Eisai Inc.8$220
Boston Scientific5$212
SK Life Science, Inc.12$172
Jazz Pharmaceuticals Inc.10$159
Abbott6$156
Medtronic(2 entities)2$153
Johnson & Johnson(2 entities)2$153
Catalyst Pharmaceuticals, Inc.2$146
EMD Serono, Inc.2$144
Teva Pharmaceuticals USA, Inc.6$110
Genentech USA, Inc.3$101
Janssen Scientific Affairs, LLC3$97
CSL Behring4$82
Takeda Pharmaceuticals U.S.A., Inc.1$76
MDD US Operations, LLC4$75
Upsher-smith Laboratories LLC5$73
Avadel CNS Pharmaceuticals, LLC3$63
Promius Pharma LLC3$58
Impel Pharmaceuticals LLC3$55
Lundbeck LLC2$51
Amneal Pharmaceuticals LLC3$46
Sanofi3$40
Bausch Health US, LLC2$37
Portola Pharmaceuticals, LLC2$35
Zyla Life Sciences, Inc.2$35
Greenwich Biosciences, Inc.2$35
Scilex Pharmaceuticals Inc.2$33
Merz North America, Inc.1$26
Pfizer1$26
Arbor Pharmaceuticals, Inc.2$23
Strongbridge US Inc.1$22
Amylyx Pharmaceuticals, Inc.1$21
Bayer1$21
GRT US Holding, Inc.1$20
Akcea Therapeutics, Inc.1$20
Axsome Therapeutics, Inc.1$19
Genentech, Inc.1$19
Chiesi USA, Inc.1$18
Acorda Therapeutics, Inc1$18
Neurocrine Biosciences, Inc.1$18
Assertio Therapeutics, Inc.1$17
ANI Pharmaceuticals, Inc.1$17
Tanabe Pharma America, Inc.1$16
Acadia Pharmaceuticals Inc1$16
Bristol Myers Squibb1$16
Averitas Pharma Inc.1$16
Aquestive Therapeutics, Inc.1$11
Aucta Pharmaceuticals, Inc.1$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981,454 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$25,987
Medicare patients
36
Services billed
2,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5014$260,287
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5034$71,974
Gamunex-CImmune Globul G/Gly/Iga Avg 4617$41,632
Pyridostigmine Bromide11$901
Gabapentin17$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$82$260,28714 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$76$71,97434 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$46$90111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →